



## **Juva Life Inc. Announces Deemed Exercise of Special Warrants and Filing of Amended and Restated Q1 Financial Statements**

VANCOUVER, BC – June 18, 2021 – **Juva Life Inc.** (CSE: JUVA, OTCQB: JUVAF, FRANKFURT: 4VV) (“**Juva**” or the “**Company**”) a California based life sciences company focused on the research, development and commercialization of cannabis products pleased to announce today the deemed exercise of 9,528,578 special warrants (the “**Special Warrants**”) issued by the Company on February 19, 2021 following the issuance of a receipt for the Company’s final short form prospectus dated June 18, 2021, filed with the securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan and Ontario.

In accordance with the terms of a special warrant indenture dated February 19, 2021 between the Company and Olympia Trust Company, each Special Warrant converted into one common share of the Company (a “**Share**”) and one-half of one common share purchase warrant (a “**Warrant**”). Each Warrant is exercisable for one Share on or before February 18, 2023 at an exercise price of \$1.35 per Share. For further information on the Special Warrants, please see the Company’s news release dated February 19, 2021, a copy of which is available on SEDAR ([www.sedar.com](http://www.sedar.com)).

The Company also announces today that it has amended and restated its interim financial statements (the “**Interim Financial Statements**”) and interim management’s discussion and analysis (the “**MD&A**”) for the three months ended March 31, 2021 and 2020. Among other items, the amended and restated Interim Financial Statements and MD&A were filed to:

- update Note 17 for events that occurred after May 28, 2021;
- include the following disclosure in the condensed consolidated interim statements of cash flows, the Company:
  - removed the amounts in the changes in other accounts receivable and proceeds received on disposition;
  - amended the cash used in operating activities and investing activities; and
  - amended the increase in cash and cash balance at the end of the period.

Except as described above, the Interim Financial Statements do not differ from the original interim financial statements.

The amended and restated Interim Financial Statements and MD&A for the indicated period are available under the Company’s profile on SEDAR at [www.sedar.com](http://www.sedar.com)

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

**About Juva Life Inc.** (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector's next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: <https://juvalife.com/>.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: [inquiries@juvalife.com](mailto:inquiries@juvalife.com)

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

### **Forward-Looking Information**

Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. These forward looking statements include, but are not limited to the intended use of the proceeds of the Offering. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on [www.sedar.com](http://www.sedar.com).